ONCODESIGN overview

Oncodesign Services, a Leading European CRO In Preclinical Drug Discovery Acquires ZoBio, A CRO Specialized in Small Molecule Drug Discovery PR Newswire DIJON, France and LEIDEN, Netherlands, Jan. 23, 2024 DIJON, France and LEIDEN, Netherlands , Jan. 23, 2024 /PRNewswire/ -- Oncodesign Services (ODS), a leading Contract Research Organization specialized in drug discovery and preclinical services, announces its international expansion through the acquisition of ZoBio, a Dutch CRO expert in...

Regulatory News: Oncodesign Services (Paris:ALONC) (FR0011766229 - ALONC), a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital (the “ Control Block “ ), from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well...

Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: MLOPM) (Paris:MLOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces that it will be listed on Euronext Access + Paris through a direct quotation on October 5, 2022. Oncodesign Precision Medicine's mission is the discovery of effective treatments for resistant and advanced cancers. It is an innovative biopharmaceutical company...

Regulatory News: Oncodesign's (Paris:ALONC) General Meeting held on September 30, 2022, authorised the distribution of OPM shares to Oncodesign shareholders. Each Oncodesign shareholder will receive one OPM share for one ONCODESIGN share held. No new shares will be issued in relation to the admission of the OPM shares to Euronext Access+. In this context, it is specified that 6,826,110 Oncodesign shares are entitled to the exceptional distribution of premiums and reserves decided at the General...

Regulatory News: Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign (ALONC - FR0011766229) (Paris:ALONC), and Oncodesign announce that Euronext Paris S.A. has authorised on September 26, 2022 the admission to listing on Euronext Access + market in Paris of OPM's ordinary shares, under the direct listing procedure in the context of the allocation of OPM shares to Oncodesign shareholders. This allocation remains subject to approval by the general meeting of Oncodesign to be held at...

Regulatory News: Servier, an international pharmaceutical company, and Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign (ALONC - FR0011766229) (Paris:ALONC) specialized in precision medicine, announce that Servier has exercised its exclusive license option for their drug candidate, an inhibitor of the LRRK2 (Leucine-Rich-Repeat Kinase 2) kinase target. In March 2019, Servier and Oncodesign started a research and development collaboration on LRRK2 kinase inhibitors, from the OPM's...

Regulatory News: Global pharmaceutical group Servier and Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign (ALONC - FR0011766229) (Paris:ALONC), announce a collaborative research agreement, named 'STarT Pancreas', to identify and validate new therapeutic targets in Pancreatic Ductal Adenocarcinoma (PDAC). The three-year agreement between Oncodesign Precision Medicine (OPM) and Servier includes two steps: Co-construction of an AI analytical platform based on data generated in the...

Regulatory News: ONCODESIGN (ALONC - FR0011766229), a biopharmaceutical group specialising in precision medicine, announces its results for the first half of 2022. Philippe GENNE, Chairman and CEO of Oncodesign, said: "Building on the momentum of previous years, Oncodesign is continuing to develop and is poised to reach a new growth milestone despite a very difficult international environment and the significant involvement of management teams in the challenging process of selling the service...